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Abstract: Cough constitutes an impressive expression of the normal defense mechanisms of 
the respiratory system. Productive cough associated with catarrh is an important protective 
system for the lung because it favors the upward movement of secretions and foreign bodies 
to the larynx and mouth. Cough may also appear without bronchial secretions, as dry cough, 
which may be persistent when inflammatory disease is chronic or when, in the early stages of 
respiratory disease, bronchial secretions are not yet fluid. Sometimes bronchitis-induced cough 
does not significantly affect quality of life, whilst in other cases cough may become so intense 
as to impair daily activities severely, resulting in permanent disability. This type of cough is one 
of the most frequent reasons for seeking medical advice. The use of cough suppressants may 
be appropriate for reaching a precise diagnosis and when dry cough is persistent. Cloperastine 
has been investigated in various types of cough and, unlike codeine, has been shown to possess 
dual activity. It also acts as a mild bronchorelaxant and has antihistaminic activity, without 
acting on the central nervous system or the respiratory center. Here we review the preclinical 
and clinical evidence of the efficacy and tolerability of cloperastine.
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Introduction
Cough is a normal mechanism for the maintenance of a healthy respiratory s  ystem,1,2 
and the nerves involved are located in two pathways, ie, an afferent limb and an e  fferent 
limb.3 The afferent pathways involve receptors located in the larynx,   throughout 
the respiratory tree, on the pleura in the hearing channel, in the nose, and in the 
paranasal sinuses, pharynx, stomach, and diaphragm, and involve the trigeminal, 
g  lossopharyngeal, phrenic, and vagus nerves.4 Cough is characterized by an initial, 
short inspiratory phase, followed by closure of the glottis and rapid expiration with 
violent expulsion of air.5 In general, it is an important defense mechanism that expels 
infectious or excessive secretions from the tracheobronchial tree, and removes and 
dislocates exudates, cellular detritus, and foreign bodies5 (see Figure 1).
Management of a cough should be directed at the underlying cause. Thus, the 
first important step is to make a differential diagnosis in order to identify the cause 
of coughing and exclude serious pathology. Different studies have demonstrated the 
existence of different receptors for mechanical, chemical, and pharmacological stimuli, 
and these respond differently to antitussive agents.4 When productive and associated 
with catarrh, cough serves as an important protective system for the lungs, because 
it favors the upward movement of secretions and foreign bodies to the larynx and 
mouth. However, cough may also occur without fluid bronchial secretions, as dry Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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cough, which may be persistent when inflammatory disease 
is chronic or when, in the early stages of respiratory disease, 
bronchial secretions are not yet fluid.1 In most cases, cough 
occurs as part of a series of symptoms that pinpoints the 
site or organ involved in the morbid process. In the case of 
acute cough, an accurate case history and objective clinical 
examination provides a diagnosis without having to resort 
to laboratory tests. In the case of chronic cough, diagnostic 
tests are required to identify both the specific etiopathogenic 
causes and nonspecific stimulus factors.5
The most frequent causes of chronic cough are cigarette 
smoke, irritants from pollutants, bronchial and pulmonary 
carcinoma, asthma, chronic obstructive pulmonary disease 
(COPD), sinusitis, gastroesophageal reflux, iatrogenic and 
psychogenic cough, and, lastly, tuberculosis, which has 
returned as a health problem.4
Any disorder resulting in inflammation, constriction, 
infiltration, or compression of the airways can be associated 
with cough. Inflammation commonly results from various 
airway infections, ranging from viral or bacterial bronchitis 
to bronchiectasis. Another common cause of cough is asthma, 
that may presenting without wheezing or dyspnea, making 
the diagnosis more difficult.
Infiltrating airway wall cancer, granulomas (eg,   sarcoidosis 
or tuberculosis), compression of the airways from extrinsic 
masses, interstitial lung disease, pneumonia, lung abscess, 
and congestive heart failure may be associated with cough.4,5 
Sinusitis causes cough due to postnatal drip of secretions into 
the trachea, gastroesophageal reflux causes nocturnal reflex 
cough, and psychogenic cough is a common symptom of 
stress, and occurs particularly in people who often speak in 
public and in children.4
Nonproductive cough is also caused by the more w  idespread 
use of antihypertensive agents, such as the a  ngiotensin-
  converting enzyme inhibitors in 5%–20% of patients taking 
these drugs,4 and is probably related to   accumulation of 
  bradykinin or substance P, resulting from the pharmacological 
activity of this class of drugs. Usually the onset of angiotensin-
converting enzyme inhibitor-related cough is within one week 
of starting the drug, but can be delayed.3
The clinical picture may help to confirm the diagnosis, 
eg, if other upper respiratory tract infection symptoms are 
present, such as rhinorrhea and sore throat. Coughing may 
be caused by infection (more likely of viral than bacterial 
etiology), croup, or tracheomalacia accompanied by a bark-
ing cough.
Pneumonia, and bronchiolitis may be accompanied by 
respiratory distress. Paroxystic cough suggests pertussis 
infection, and a temporal association with feeding or with 
positioning should indicate gastroesophageal reflux.2
Asthma 
Sinusitis
Allergy
Emphysema
Laryngitis 
Pneumonia  
Lung cancer  
Tuberculosis    Pulmonary
edema
Heart failure 
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Duration of the cough may be helpful:
•	 Acute cough (for less than three weeks before diagnosis) 
is most often due to upper respiratory infection, but more 
serious diseases, such as pneumonia, pulmonary embo-
lism, or congestive heart failure, cannot be ruled out
•	 Subacute cough (for 3–8 weeks) is more commonly 
postinfectious, due to persistent airway inflammation 
and/or postnasal drip
•	 Chronic cough (more than 8 weeks) may suggest COPD or 
bronchogenic carcinoma in smokers, while in nonsmok-
ers (not taking angiotensin-converting enzyme inhibitors 
and with a normal chest radiograph) the most common 
causes of chronic cough are postnasal drip, asthma, and 
gastroesophageal reflux.3
Symptomatic treatment with antitussives is usually 
employed if the cough is nonproductive, barking, and 
  significantly interferes with the well-being of the pediatric 
or adult patient (causing, eg, nausea, vomiting, insomnia, 
and/or headache). Antitussives can be divided into two main 
categories depending upon whether the mechanism of action 
is central or peripheral. Central antitussives include narcotics 
and non-narcotics, and act more or less s  electively on the 
cough center located in the medulla oblongata. Non-narcotic 
therapy is preferable in children, because narcotic   antitussives 
(eg, levorphanol, codeine) may cause respiratory center 
depression, nausea, vomiting, constipation, addiction, and 
physical dependency.5
The therapeutic strategy should treat the cough with 
suitable pharmacological therapy, taking into account the 
nature and etiology of the cough. In addition, the treatment 
should have a sustained action throughout the day, and should 
preserve sleep quality at night time.4
Mucolytics are often prescribed as adjuvant therapy to 
eliminate catarrh in chronic and acute bronchitis, bronchial 
asthma, and bronchiectasis.4 Some of the most common ones 
used are cysteine derivatives, eg, N-acetylcysteine, which 
can break the sulfide links between glycoproteins and loosen 
mucus.6,7 Antitussives are mainly used to treat chronic persis-
tent dry cough when the etiology is a chronic p  athology.8–10 
Among the antitussive agents, cloperastine, which possesses 
antitussive and antiedemic activity, also relaxes the bronchial 
musculature. Unlike codeine, cloperastine is not a narcotic, 
acts directly on the cough center, does not possess local anes-
thetic activity, and does not depress the respiratory center.8
Some of the centrally acting opioid derivatives used 
today include dextromethorphan, noscapine, codeine, and 
dihydrocodeine, which may lead to dependency and, in rare 
cases, halt breathing, especially in the elderly.4 Even though 
they are often available as commercial syrups, expectorants, 
and antitussives, these products should not be used together 
because they counteract each other.4
The US Food and Drug Administration (FDA) has 
advised against the use of over-the-counter cough and cold 
medicines in children younger than two years of age, and 
recommended caution when using such medicines in chil-
dren aged 2–11 years because of the risk of life-threatening 
adverse effects (FDA Public Health Advisory 2008). It is 
preferable not to use these agents in children of any age, par-
ticularly in the presence of neurological disorders,   seizures, 
hypotonia, heart disease, and in view of the risk of respiratory 
depression (see FDA warning).
Therefore, it is imperative to check whether it is appropriate 
to prescribe cough and cold medicines for children. For pedi-
atric patients is no reliable evidence to recommend cough 
and cold medicines in children younger than two years of 
age, although most clinical studies have been performed in 
older children.2
In addition, a Cochrane review9 including two trials 
with antitussives (dextromethorphan and codeine), two 
with antihistamines (clemastine and chlorpheniramine, 
diphenhydramine), two with antihistamine-deconges-
tants (brompheniramine-phenylbropanolamine and 
brompheniramine-phenylephrine-propanolamine), and 
one with an antitussive-bronchodilator combination 
(dextromethorphan–salbutamol) found that these treatments 
were no more effective than placebo for acute cough in chil-
dren. Another Cochrane review found insufficient evidence 
to establish whether over-the-counter medicines were help-
ful for cough when associated with antibiotic use for acute 
pneumonia in children and adults.10 Moreover, although most 
of the trials included in the Cochrane reviews did not report 
adverse events, it is well known that cough and cold products 
in children are a major cause of unintentional drug overdose,11 
and are associated with mortality. Indeed, during 2004–2005, 
1519 children younger than two years of age were treated in 
US emergency departments for adverse events associated with 
cough and cold medications. Because of the risk of toxicity, 
lack of dosing recommendations, and limited evidence for the 
effectiveness of these drugs in children younger than two years, 
clinicians should exercise caution when prescribing them, and 
warn parents and caregivers about these concerns.12
Cloperastine
Cloperastine (1-[2-(p-chloro-alpha-phenylbenzyloxy)ethyl]
piperidine) is a drug with a central antitussive effect, and is 
also endowed with an antihistaminic (sharing an ethylamine Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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moiety with H1 receptor antagonists) and papaverine-like 
activity similar to codeine but without its narcotic effects. 
Pharmacological studies have shown that the molecule acts 
on the cough center without depressing the respiratory center, 
and that it has no negative cardiocirculatory effects.13 The 
initial response at the therapeutic dose range (10–20 mg 
three times daily for adults) is 20–30 minutes after oral 
administration. Moreover, the duration of action of a single 
dose of cloperastine is 3–4 hours. Further pharmacokinetic 
information is provided in the Table 1.
Preclinical studies
Cloperastine was first studied by Takagi et al at the Uni-
versity of Tokyo.14 This research group investigated the 
pharmacological activity of several derivatives of diphen-
hydramine, an antihistamine substance, and discovered 
that cloperastine had the greatest efficacy against cough 
caused by tracheal mechanical stimulus in the guinea pig. 
This effect was 1.9 times greater than codeine, without any 
narcotic effects.
In a later study conducted in dogs and cats, the same 
researchers showed that the activity of cloperastine spe-
cifically involved the cough center, without interfering with 
the respiratory center. Cloperastine, which also possesses 
bronchorelaxant and antihistaminic activity, helped to relax 
the bronchial musculature which had become tight due to 
stimulation by acetylcholine and histamine.14 In particular, it 
was shown that cloperastine was able to induce a significant 
and dose-dependent reduction in the number of coughing fits 
induced in guinea pigs by NH3 or citric acid vapor, and its 
antitussive activity appeared similar to that of codeine in this 
experimental model. The antihistaminic effect of cloperastine 
is demonstrable in guinea pigs by a histamine aerosol-induced 
bronchospasm test.14 The drug is able to antagonize tracheal 
chain contractions induced by various agonists in guinea pigs, 
thus having a muscle relaxant effect, particularly remarkable 
in histamine-induced contractions, but appears to be free of 
any influence on spontaneous m  otility.14 C  loperastine also 
shows good toxicological c  haracteristics, without addiction 
potential, thus having promise for t  herapeutic use.14 In rats, 
the drug is metabolized in the liver and kidneys, where most 
of it is eliminated within 24 hours of a  dministration. The drug 
reaches maximal concentration in the liver within two hours of 
ingestion, and is mainly eliminated by g  lycuronoconjugation.14 
Cloperastine hydrochloride shows relatively low acute t  oxicity 
when administered by the i  ntraperitoneal route in rats and 
mice, and shows minor toxicity by the oral route when 
administered as cloperastine fendizoate, the LD50 in rats and 
mice for the two administration routes exceeds 1000 and 
2000 mg/kg, respectively.14 The acute toxicity picture seen 
is mainly localized at level of the central nervous system, 
including depression and sedation. Chronic toxicity tests 
performed in rats treated for three months with cloperastine 
hydrochloride 15 mg/kg and 45 mg/kg and cloperastine 
f  endizoate 100 mg/kg and 300 mg/kg, and in dogs treated 
for three months with cloperastine hydrochloride 20 mg/kg 
and cloperastine fendizoate 100 mg/kg, revealed no   particular 
symptomatology or variations in hematochemical, hemato-
logical, and urinary parameters with respect to control animals 
and baseline values (unpublished data). Post mortem as well 
as macroscopic and microscopic examination also showed no 
evidence of pathological changes affecting the main organs 
and parenchyma.14
The possible activity of cloperastine in terms of both fetal 
toxicity and teratogenesis in rats and rabbits was also   considered. 
Such tests did not demonstrate significantly   different effects 
from those observed in control animals. Of interest are the 
pharmacokinetic characteristics of c  loperastine, which reaches 
plasma levels within one hour of administration. Eight hours 
after intake, the drug is still detectable in plasma and for 
about six hours in tissues and parenchyma. It is completely 
m  etabolized in a short time and is mainly excreted in the 
urine as metabolites. It is in this context that the investigations 
performed by Takagi et al took place, aiming to evaluate the 
pharmacodynamic activity of the molecule, and in particular its 
antitussive effect.14 Cloperastine proved to reduce the number of 
Table 1 Pharmacokinetics of cloperastine*
Onset and duration initial response oral: 20–30 minutes (Prod info Nitossil®, 1997)
Duration single oral dose: 3–4 hours (Prod info Nitossil®, 1997)
Drug concentration levels Time to peak concentration oral tablet: 60–90 minutes15
Adsorption Rapidly absorbed from oral administration (Prod info Nitossil®, 1997; Prod info Quik® 1997)
Metabolism extensive hepatic metabolism (Prod info Seki®, 1986)
excretion Renal excretion; metabolites are eliminated by renal excretion15
Biliary excretion; metabolites are eliminated in the bile within 24 hours after administration 
(Prod info Nitossil®, 1997)
Note: *Micromedex, last access October 25, 2010.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
87
Cough and cloperastine
coughing fits induced in guinea pigs significantly, even at a dose 
of 1 mg/kg, and this activity was shown to be superimposable on 
that of codeine. With regard to potential antihistaminic action, 
the drug was shown to have high antihistaminic activity in the 
histamine aerosol-induced bronchospasm test.14 This activity, 
which was greater at the dose of 5 mg/kg, was present also at the 
dose of 1 mg/kg, thus demonstrating remarkable efficacy as an 
antihistaminic agent.14 In addition, both the hydrochloride and 
fendizoate salts of cloperastine were able to induce a significant 
and dose-dependent increase in sleep duration, but failed to 
increase significantly the time taken to disappearance of the 
righting reflex.14 Finally, the addiction potential of cloperastine 
was studied in animals addicted to morphine. These tests did not 
show a particular involvement of spontaneous motility in rats 
during four hours of r  ecording, whilst codeine induced a marked 
increase in motility during the first hour of treatment. This is 
particularly important chronically, because it demonstrated 
a cross-dependence between codeine and morphine, whilst 
cloperastine induced no morphine-like dependence.14
Cloperastine in treatment  
of chronic cough
Many patients suffer chronically from this disturbing and 
debilitating symptom caused by the excessive production 
of mucus or an increased central response reflex. However, 
cough must be treated if its intensity becomes excessive and 
debilitating. Nonetheless, symptomatic treatment is difficult, 
and although drug therapy should target the etiology of the 
illness (eg, treatment with antibiotic and/or antiasthmatic 
therapy), in most cases this will not alleviate cough if there 
is no underlying cause.
Therefore, definitive treatment for cough depends 
p  rimarily on its specific cause and the adoption of a specific 
therapy. Even if the etiologic therapy induces symptomatic 
remission, a nonspecific antitussive therapy may be required, 
especially in a patient suffering from a chronic disease.
It is true that the cough mechanism in chronic bronchitis 
partially compensates for the minor efficacy of the muco-
ciliary depuration mechanism, which appears particularly 
impaired in these patients, due to the reduction in numbers 
of cilia. For this reason, the use of cough sedatives is not 
recommended for patients with chronic bronchitis in the 
exacerbation phase and with copious expectoration.8–10
Various studies have demonstrated clearly that c  loperastine, 
which is free of narcotic activity and does not depress the 
respiratory center, has significant t  herapeutic activity against 
cough due to various pathologies, causing no respiratory 
depression and not interfering with protective mucociliary 
mechanisms.15 In a clinical study, Camisasca et al15 e  valuated 
cloperastine in 23 patients with scarcely productive but per-
sistent cough. Cloperastine 20 mg as a single evening dose 
was chosen to enable better night-time rest by eliminating 
coughing fits and avoiding, in the meantime, depression of 
the tracheobronchial depuration mechanism during the day 
time. The majority of the treated patients showed a significant 
subjective improvement, documented by a clear reduction in 
previously troublesome night-time cough. No concomitant 
changes in partial oxygen or carbon dioxide pressures were 
reported, confirming that cloperastine does not have a n  egative 
effect on respiratory function.
Furthermore, Olivieri et al evaluated the efficacy of clo-
perastine in a double-blind study of 30 patients with chronic 
bronchopneumonia, tuberculosis, or bronchopulmonary 
malignancy, selected based on their cough frequency and 
intensity.13 The patients were randomized to receive cloperas-
tine or placebo at the dose of 20 drops (equivalent to 35.4 mg 
of the active substance) three times per day for nine days. The 
investigators clearly demonstrated the ability of cloperastine 
to reduce and control cough symptoms for the entire duration 
of the study. Improvement in cough, in turn, had a positive 
effect on night-time rest. Cloperastine does not appear to 
affect the volume, appearance, and v  iscoelastic properties of 
sputum, which underwent similar, positive changes in both 
groups of patients. This effect is attributable to the activity 
of baseline therapy during the hospital stay. The progression 
of respiratory rate and spirometric index values was also 
consistent, as were blood pressure and heart rate values, 
demonstrating that the antitussive effect of the drug is not 
accompanied by changes in cardiorespiratory function.13
Furthermore, in another clinical study of 21 patients with a 
range of bronchopulmonary illnesses and presenting with cough 
that required antitussive therapy, Fabris evaluated the efficacy 
of cloperastine administered for an average of 9 (range 3–16) 
days.16 However, based on the fact that the patient cases in the 
study varied in severity and diagnosis, the activity of the drug 
was rated by considering the individual patients on the one 
hand and the overall results on the other. Fabris demonstrated 
that, in most cases, 40 mg, or one 10 mg dose of cloperastine 
twice per day plus two pills at bedtime, was sufficient to control 
cough, including t  hroughout the night.16 Considering the overall 
score as described by Fabris,16 there was a significant reduction 
in cough as early as one day after the start of treatment, with a 
further s  ubsequent r  eduction. This reduction was   attributed not 
only to the efficacy of the drug, but also due to amelioration of 
the illness as it ran its course. Almost none of the patients had 
cough by day 11 of the study. Despite complete resolution of Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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cough, treatment was continued for a few days in some patients 
because they still required some   pharmacological cover. Report-
ing the results of this study in percentages, 66.7% of the subjects 
showed a maximum effect, 28.6% had a fair–satisfactory effect, 
and 9.5% had no effect. Moreover, cloperastine was shown to be 
particularly effective even in the most severe cases, such as lung 
cancer.16   Tolerability was excellent in all cases; only one subject 
could not be evaluated because treatment was stopped after 
three days due to lack of efficacy of the drug. There were no side 
effects, such as dry mouth, constipation, or intestinal problems. 
There were no statistically significant changes in blood pressure, 
heart rate, or any of the other biohumoral parameters studied. 
This research confirms the therapeutic efficacy and tolerability 
of cloperastine. It should also be pointed out that none of the 
patients experienced respiratory depression, and some subjects 
experienced antispastic bronchial activity while taking the 
drug. Another interesting aspect of the activity of cloperastine 
observed in this study was that it does not negatively affect the 
amount of mucus produced or its fluidity.16
In another double-blind investigation, cloperastine was 
shown to be effective as an antitussive in four tracheostom-
ized patients, with no reported side effects.17 In particular, 
the authors of this study also pointed out that the two for-
mulations of cloperastine used (ie, sugar-coated tablets and 
syrup) did not differ from each other in activity.
The beneficial effect of cloperastine has also been dem-
onstrated in a multicenter, randomized, placebo-controlled 
study in 100 patients suffering from chronic or persistent dry 
or productive cough, resulting from acute and chronic respira-
tory tract disease.1 In this study, the authors reported signifi-
cant subjective improvement, demonstrated by reduction of 
cough frequency and severity and a decrease in night-time 
cough, together with improvement in night rest, in patients 
treated with cloperastine three times daily and with a double 
dose in the evening.1
Importantly, a recent study has demonstrated the 
e  xistence of different receptors for mechanical, chemical, 
and pharmacological stimuli, which respond differently to 
antitussive agents.4 Codeine remains the standard antitussive 
therapy but may lead to dependency and, in rare cases, halt 
breathing, especially in the elderly. In a controlled clinical 
study, Margarino et al evaluated the activity of c  loperastine 
versus codeine in a “intent to treat” population of patients 
who were being monitored for a variety of reasons, and all 
had persistent chronic cough.4 This study randomized 156 
patients to cloperastine syrup or dihydrocodeine, and it was 
reported that cloperastine had more significant activity. 
Moreover, the authors recommended that, because the com-
parator was codeine and that the effects were measured in 
patients with an extensive case history of illness, cloperastine 
should be considered among the drugs of first choice for 
cough. Cloperastine meets the requirements of rapid action, 
maximum manageability, tolerability, and improvement in 
the quality of sleep, the latter being a very important feature 
in pediatric and debilitated adult patients. The authors sug-
gested that cloperastine could be used safely for four days at 
a time.18 Furthermore, in another controlled clinical study19 
in 38 outpatients with cough of various causes treated with 
codeine or cloperastine pills/chewable tablets, the efficacy 
of cloperastine in the symptomatic treatment of cough was 
also confirmed.
Importantly, cloperastine is as active as codeine, which 
has been the drug of choice for treating cough for years due to 
its overall sedative action on cough. In addition, cloperastine 
is highly effective for improving night-time rest disturbed by 
cough. These results confirm the value of the double dose at 
night time. Unlike codeine, cloperastine has an additional 
mild bronchorelaxant effect, which is useful in patients pre-
senting with spastic airways. Both cloperastine preparations 
were shown to be equally active, improving compliance with 
treatment because the patient can choose the most suitable 
formulation.19
Finally, in a controlled, double-blind, clinical study, Ghir-
inghelli investigated the efficacy of cloperastine in patients 
with exacerbation of COPD.20 In the exacerbation phase of 
COPD, cough frequently appears as not purposive, namely 
nonproductive and wearying. This symptom therefore 
requires specific pharmacological intervention, enabling 
rapid control, while waiting for antibiotic therapy to treat 
the underlying cause. In such circumstances, evaluation of 
the efficacy of an antitussive preparation should take into 
account the response of the underlying disease to antibiotic 
therapy. To this end, the authors compared the effects of clo-
perastine with those of butamirate under analogous experi-
mental conditions and at full therapeutic dosage and proven 
efficacy. This enabled the evaluation of cloperastine alone 
and also an evaluation of any possible difference between 
the effects of cloperastine and butamirate. The study of the 
“acute” effect, namely the response to the first dose of the 
drug, a parameter that can be considered to be independent 
of the course of the underlying disease, showed that clop-
erastine could reduce cough frequency and intensity. The 
superiority of cloperastine compared with butamirate was 
clinically evident and statistically demonstrable on the first 
and second days of treatment, taking into consideration the 
three symptom-related parameters examined (ie, frequency Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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and intensity of cough during the day, rest disturbed by 
cough during the night). Finally, it is interesting to observe 
that, from the third day onwards, there was no statistically 
significant difference in cough control in the two groups, 
which may be the time frame in which antibiotic therapy 
takes effect and helps to bring cough under control. Thus, 
cloperastine was very effective as an antitussive agent in 
patients with exacerbation of COPD, allowing satisfactory 
symptomatic control from the first day of treatment in 65%, 
from the second day in 20%, and from the third day in 10% 
of cases. A useful therapeutic effect was therefore achieved 
in 95% of cases. Cloperastine administered three times 
daily was shown to be able to control cough effectively, 
not only during the day time but also during the night time. 
In addition, cloperastine has excellent tolerability, with no 
undesirable effects reported either at a clinical or biohumoral 
level.20 In conclusion, the results of all these studies confirm 
the favorable therapeutic index of cloperastine, and position 
it among the drugs of first choice for conditions in which a 
cough sedative is required.
Cloperastine for children  
with chronic cough
Respiratory tract infection is one of the most common causes 
of illness in children, and cough and fever are the most fre-
quent symptoms that worry parents. Symptomatic therapy 
is appropriate in the case of a pointless, nonproductive, 
persistent cough caused by bronchial irritation, which often 
greatly disturbs the well being of young patients, and can be 
a  ssociated with nausea, vomiting, insomnia, and headache.5 
Non-narcotic therapy is preferable in children because narcotic 
antitussives (codeine, dihydrocodeine) may cause respiratory 
depression, nausea, vomiting, constipation, addiction, and 
physical dependency. The clinical studies described earlier 
have clearly demonstrated that cloperastine acts directly on 
the cough center without depressing the respiratory center and 
without affecting the cardiocirculatory system.5
It is widely agreed that it is necessary, if not imperative, 
to conduct controlled, double-blind clinical studies to docu-
ment the efficacy of symptomatic drugs such as antitussives 
specifically in children. Scotti and Borzani5 undertook a 
controlled, double-blind clinical efficacy study in children 
with cough secondary to acute bronchitis, and also attempted 
to define the optimal dose of cloperastine in accordance with 
the age and/or weight of the patients treated. The latter aspect 
is particularly important, because pediatric therapy must be 
administered in accordance with patient weight. This study 
had several important findings. Cloperastine was effective 
for settling irritative cough secondary to acute bronchitis. 
Cough intensity was reduced, expectoration was facilitated, 
and there was a significant improvement in auscultatory 
findings, confirming the efficacy of cloperastine. Lastly, a 
particularly valuable result was the posology used, which 
consisted of three administrations per day with a double dose 
in the evening, increasing the effect of the drug during the 
night to render sleep more restful and improving the overall 
well-being of the child.5
Similarly, in a single-blind study of 30 children aged 
5–12 years with respiratory tract inflammation, Cicchetti21 
confirmed that cloperastine is a highly effective treatment for 
children with persistent cough interfering with night-time rest. 
The tolerability of cloperastine was consistently good.20
Furthermore, in a randomized, double-blind, placebo-
controlled study, Svitaylo evaluated the clinical efficacy and 
tolerability of cloperastine in children with nonproductive 
cough caused by respiratory tract infection.22 The study 
enrolled 200 patients, and included a placebo group to define 
the activity of the drug better. The dosage regimen and dura-
tion were the same as those normally used for cloperastine 
in clinical practice. The results of this study confirmed the 
antitussive activity of cloperastine fendizoate in children and 
adolescents with upper and lower respiratory tract infection 
in whom a nonproductive, persistent cough was one of the 
key symptoms that caused medical help to be sought. The 
therapeutic activity of cloperastine, which had already been 
evaluated in other controlled clinical studies, was investigated 
for both primary endpoints (cough intensity and frequency) 
and secondary endpoints (interference in duration and quality 
of sleep for the patient and parents). At the final visit, cough 
was absent in 80.4% of patients treated with cloperastine 
versus 10.4% of patients treated with placebo. Reduction of 
cough, which was homogenous in both arms of the study at 
the baseline visit, occurred rapidly in the cloperastine group, 
and the frequency of night-time cough, which made parents 
particularly anxious, decreased rapidly within the first three 
days of treatment. However, at various time points, mean 
scores were similar to those found during the first night of 
evaluation in the placebo arm, reinforcing that the improve-
ment in cough seen in the cloperastine arm was due to the 
pharmacological activity of the drug and not attributable to 
spontaneous cough reduction.
Improvement or disappearance of cough is obviously 
reflected in quality of sleep for the child and parents, 
and examination of these endpoints showed a significant 
r  eduction in mean scores obtained in the cloperastine arm 
versus the placebo arm. The significant improvements Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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obtained in all the endpoints evaluated were confirmed by 
the overall rating of the principal investigator who, blinded to 
the study, rated cloperastine treatment as excellent in 90.2% 
and good in 9.8% of subjects. The difference in the positive 
rating obtained in the placebo arm was very significant, both 
statistically and clinically.
The frequency of respiratory illnesses from colds, 
which is particularly high in children during winter, is 
often accompanied by a dry, barking cough leading to the 
widespread use of antitussives. Parents contribute to this 
by independently administering antitussives in order to 
alleviate the frequency and intensity of the cough, which 
has a negative effect on their quality of sleep, too, and thus 
on the performance of their daily activities.22 On the other 
hand, the literature contains ambiguous information about 
the activity and tolerability of these drugs. Codeine and 
dextromethorphan are widely used as antitussives and are 
not recommended by the American Pediatric Association 
due to a lack of conclusive proof of their benefit and their 
potential toxicity.23,24 D  extromethorphan is a centrally acting 
opioid which is widely used as an a  ntitussive. It has been 
shown to be effective in children with upper respiratory 
tract infection, but more recent studies have found it to be 
no better than placebo for controlling acute cough. Even 
studies in adults with upper respiratory tract infection have 
not provided consistent results, and there have also been 
conflicting results for the antitussive activity of diphenhy-
dramine, an antihistamine.
Of particular interest is a recent US study conducted 
in children with cough caused by upper respiratory tract 
i  nfection, which evaluated the antitussive activity of 
d  extromethorphan, diphenhydramine, and placebo on the 
frequency and severity of cough in pediatric patients and 
on the interference of this symptom with their sleep and the 
sleep of their parents. Despite improvement being found in 
all three groups for the endpoints evaluated, neither diphen-
hydramine nor dextromethorphan produced a significantly 
superior benefit over placebo.23
The literature reports various adverse events associ-
ated with the use of antitussives. Dystonia,25 anaphylactic 
reaction,26 and bullous mastocytosis27 have been seen 
with dextromethorphan, and this drug has also been 
abused28,29 by young adolescents. Therapeutic doses of 
diphenhydramine have been associated with sleepiness, 
and also nervousness, restlessness, insomnia, acute dys-
tonia, impaired driving a  bility, and increased risk of seri-
ous injury with standard doses. Adverse events such as 
nausea, vomiting, vertigo, sedation, palpitations, pruritus, 
and constipation have been seen with antitussive doses of 
codeine and dihydrocodeine,18 and potentiation phenomena 
with other centrally acting sedatives, such as anxiolyt-
ics and tricyclic antidepressants, have also been seen. 
The results of a placebo-controlled study conducted in a 
large number of patients demonstrate that c  loperastine is 
among the drugs of first choice for the treatment of cough 
in children and adolescents with upper respiratory tract 
infection due to its efficacy, rapid action, and tolerability. 
Of particular interest is the effect of the drug on night-time 
sleep, with improvement in quality and duration of sleep 
and night-time rest, and also that of parents. In this regard, 
Seidita et al have evaluated the efficacy and tolerability of 
cloperastine syrup in a controlled clinical pediatric study 
versus control therapy based on syrup containing codeine 
and phenyltoloxamine for a total of seven days.30 The use 
of a well established and effective comparator drug in this 
study led to a more accurate and thorough e  valuation of the 
antitussive activity of cloperastine. The results showed that 
both drugs had a positive effect on cough, but a c  omparison 
of the treatments demonstrated that cloperastine reduced 
the cough symptom more rapidly, which obviously led 
to a faster improvement in night-time rest, with better 
well-being in the children. lt is important to control the 
cough symptom rapidly in these inflammatory respiratory 
illnesses if it is particularly severe while waiting for the 
therapy to cure the underlying cause. Respiratory rate and 
spirometric index measurements in all patients returned 
into the normal range, accompanied by an improvement 
in the bronchial airways due to the basic therapy, which 
confirmed that the two drugs do not depress the respiratory 
center at the therapeutic dosages used. In fact, probably 
due to its spasmolytic action in the bronchial airways, clo-
perastine seems to produce an earlier and more consistent 
improvement in respiratory function which is very slightly 
ascertainable, if at all, in the spirometric tests performed 
only at the end of treatment.
In a clinical study of 20 patients aged 2–14 years, 
Barbato et al also demonstrated that cloperastine was 
immediately effective in reducing cough, and acted par-
ticularly rapidly in night time cough, and significantly 
improved night-time rest of the children.31 The drug was 
well tolerated in this study due to lack of changes in respi-
ratory and c  ardiocirculatory p  arameters, which was also 
confirmed by the laboratory data. The therapeutic activ-
ity of cloperastine is thus similar to codeine but without 
serious side effects, ie, nervousness, agitation, confusion, 
and convulsions.31Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Efficacy and safety summary
Clinical studies have shown that cloperastine is well toler-
ated and effective in the treatment of cough due to various 
etiologies, decreasing the frequency and intensity of cough 
of this bothersome symptom, albeit in small patient 
p  opulations.15–19,32 Moreover, cloperastine has shown potential 
advantages over opioid antitussives, which frequently cause 
sedation and respiratory depression, having comparable 
activity, but without the typical undesirable side effects.5
The efficacy of cloperastine was compared with the 
analog, levocloperastine, in open clinical trials, and demon-
strated a comparable efficacy and tolerability profile.33
However, it is important to monitor signs and s  ymptoms, 
ie, relief of cough, dyspnea, quantity and quality of 
s  putum,17–19,34 respiratory rate, forced expiratory volume in 
one second, and residual volume.13 Moreover, in children it is 
appropriate to monitor body weight, cardiac and respiratory 
rate, blood pressure, sputum quality, dyspnea, and difficulty 
in expectoration.5
Finally, there has been one case report of a patient with acute 
dystonia associated with ingestion of cloperastine syrup, who 
also suffered from schizophrenia but had been neuroleptic-free 
for six months, suggesting a possible alteration of the balance 
between dopamine and acetylcholine in the striatum.35
Conclusion
Based on the clinical evidence, cloperastine is an effective 
drug for cough, after excluding or treating underlying causes. 
Its activity appears to be rapid and the drug contributes to 
improvement in the clinical picture and well-being of patients, 
as well as improvement in night-time sleep. Finally, its good 
  tolerability and availability in syrup, drop, and tablet formula-
tions (the last being only for adult administration), confirm that 
cloperastine can be used in a wide selection of the p  opulation 
(children, adolescents, and adults), according to the indications 
on the labeling and appropriate case-by-case e  valuation. The 
efficacy and safety of cloperastine in the approved indication 
and recommended dose range have now been demonstrated 
during more than 40 years of clinical use.
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